At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
Scottline helps healthcare organizations establish a secure, agile digital infrast...
Scottline helps healthcare organizations establ...
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on th...
Sinovac Biotech Ltd. is a China-based biopharma...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
Join the National Investor Network and get the latest information with your interests in mind.